Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2012

View Archived Issues

Rexahn Pharmaceuticals obtains clearance for first-in-human RX-3117 study

Tesetaxel is active in patients with gastroesophageal cancer

Therapeutic investigation of dacomitinib expands to gastric cancer

MLN-8237 investigated with cisplatin in gastrointestinal cancer models

Alantos identifies potent disease-modifying candidate osteoarthritis drug

BrainStorm reports initial safety and efficacy data on NurOwn stem cell product

Vivalis and Sanofi Pasteur extend collaboration

Noscira completes randomization in tideglusib study

New Japanese approval of controlled-release paroxetine product

Trimel Pharmaceuticals advances phase III CompleoTRT study

Novelos Therapeutics starts phase Ib trial of radiotherapeutic agent in advanced solid tumors

Bristol-Myers Squibb patents novel chemokine CCR1 receptor ligands

Novel chemokine CCR2 receptor antagonists disclosed by Janssen

Chilean team presents new biomarker of gastric cancer progression

New insulin-like growth factor 1 receptor antagonists designed in Japan

FOB Synthesis claims new antibacterial agents

New PET imaging agents synthesized by Bracco Imaging

Trimesta studied in new phase II trial for cognitive dysfunction in MS

FDA clears clinical testing of oral epidermal growth factor receptor mutant-selective inhibitor

Hybrigenics files clinical trial application for inecalcitol in CLL

New JTE-013 analogues prepared in Italy

Ferrer cleared to begin phase III trials of ozenoxacin cream

Cell Therapeutics anticipates CHMP's opinion on Pixuvri MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.